Table 2 Association between clinicopathological characteristics of breast cancer patients and CDKN2B-AS1 genotypes
Characteristics | Total | A/A | A/G | G/G | P-value |
|---|---|---|---|---|---|
Demographics and risk factors | |||||
 Age (years) | |||||
  ≤ 45 | 98 (48.3) | 8 (44.4) | 24 (58.5) | 26 (51) | 0.38 |
  > 45 | 105 (51.7) | 10 (55.6) | 17 (41.5) | 25 (49) |  |
 Smoking | |||||
  Negative | 99 (90) | 18 (100) | 37 (90.2) | 44 (86.3) | 0.248 |
  Positive | 11 (10) | 0 (0) | 4 (9.8) | 7 (13.7) |  |
 Weight | |||||
 Underweight | 12 (10.9) | 4 (22.2) | 4 (9.8) | 4 (7.8) | 0.004 |
  Normal | 28 (25.5) | 7 (38.9) | 13 (31.7) | 8 (15.7) |  |
  OW/Obese | 70 (63.6) | 7 (38.9) | 24 (58.5) | 39 (76.5) |  |
 FH cancer | |||||
  Negative | 76 (69.1) | 13 (72.2) | 28 (68.3) | 35 (68.6) | 0.951 |
  Positive | 34 (30.9) | 5 (27.8) | 13 (31.7) | 16 (31.4) |  |
 Breast problems | |||||
  Negative | 102 (92.7) | 18 (100) | 38 (92.7) | 46 (90.2) | 0.387 |
  Positive | 8 (7.3) | 0 (0) | 3 (7.3) | 5 (9.8) |  |
 OCP intake | |||||
  Negative | 87 (79.1) | 17 (94.4) | 29 (70.7) | 41 (80.4) | 0.114 |
  Positive | 23 (20.9) | 1 (5.6) | 12 (29.3) | 10 (19.6) |  |
 Menarche | |||||
  Late onset | 39 (35.5) | 4 (22.2) | 11 (26.8) | 24 (47.1) | 0.058 |
  Early onset | 71 (64.5) | 14 (77.8) | 30 (73.2) | 27 (52.9) |  |
 Parity | |||||
  Multipara | 96 (87.3) | 14 (77.8) | 37 (90.2) | 45 (88.2) | 0.401 |
  Nullipara | 14 (12.7) | 4 (22.2) | 4 (9.8) | 6 (11.8) |  |
 Gravida | |||||
  Early G1 | 105 (95.5) | 18 (100) | 38 (92.7) | 49 (96.1) | 0.443 |
  Late G1 | 5 (4.5) | 0 (0) | 3 (7.3) | 2 (3.9) |  |
 Menopause | |||||
  Early | 98 (89.1) | 16 (88.9) | 37 (90.2) | 45 (88.2) | 0.953 |
  Late | 12 (10.9) | 2 (11.1) | 4 (9.8) | 6 (11.8) |  |
 Breast feeding | |||||
  Negative | 92 (83.6) | 13 (72.2) | 34 (82.9) | 45 (88.2) | 0.284 |
  Positive | 18 (16.4) | 5 (27.8) | 7 (17.1) | 6 (11.8) |  |
 Menopausal status | |||||
  Pre | 80 (72.7) | 14 (77.8) | 28 (68.3) | 38 (74.5) | 0.698 |
  Post | 30 (27.3) | 4 (22.2) | 13 (31.7) | 13 (25.5) |  |
 Night work | |||||
  Negative | 97 (88.2) | 16 (88.9) | 36 (87.8) | 45 (88.2) | 0.993 |
  Positive | 13 (11.8) | 2 (11.1) | 5 (12.2) | 6 (11.8) |  |
 Sedentary life style | |||||
  Negative | 11 (10) | 1 (5.6) | 3 (7.3) | 7 (13.7) | 0.470 |
  Positive | 99 (90) | 17 (94.4) | 38 (92.7) | 44 (86.3) |  |
Pathological data | |||||
 Side | |||||
  Right | 70 (63.6) | 11 (61.1) | 27 (65.9) | 32 (62.7) | 0.92 |
  Left | 40 (36.4) | 7 (38.9) | 14 (34.1) | 19 (37.3) |  |
 Site | |||||
  Outer quadrants | 48 (43.6) | 5 (27.8) | 16 (39) | 27 (52.9) | 0.13 |
  Others | 62 (56.4) | 13 (72.2) | 25 (61) | 24 (47.1) |  |
 No masses | |||||
  Single | 85 (77.3) | 12 (66.7) | 30 (73.2) | 43 (84.3) | 0.22 |
  Multiple | 25 (22.7) | 6 (33.3) | 11 (26.8) | 8 (15.7) |  |
 Grade | |||||
  ≤ 2 | 90 (81.8) | 16 (88.9) | 32 (78) | 42 (82.4) | 0.60 |
  > 2 | 20 (18.2) | 2 (11.1) | 9 (22) | 9 (17.6) |  |
 T stage | |||||
  ≤ 3 | 79 (71.8) | 12 (66.7) | 29 (70.7) | 38 (74.5) | 0.80 |
  > 3 | 31 (28.2) | 6 (33.3) | 12 (29.3) | 13 (25.5) |  |
 N stage | |||||
  N0 | 30 (27.3) | 8 (44.4) | 10 (24.4) | 12 (23.5) | 0.20 |
  N1–3 | 80 (72.7) | 10 (55.6) | 31 (75.6) | 39 (76.5) |  |
 M stage | |||||
  M0 | 50 (45.5) | 8 (44.4) | 17 (41.5) | 25 (49) | 0.76 |
  M1 | 60 (54.5) | 10 (55.6) | 24 (58.5) | 26 (51) |  |
 LVI | |||||
  Negative | 58 (52.7) | 10 (55.6) | 18 (43.9) | 30 (58.8) | 0.35 |
  Positive | 52 (47.3) | 8 (44.4) | 23 (56.1) | 21 (41.2) |  |
 Skin involvement | |||||
  Negative | 89 (80.9) | 14 (77.8) | 31 (75.6) | 44 (86.3) | 0.40 |
  Positive | 21 (19.1) | 4 (22.2) | 10 (24.4) | 7 (13.7) |  |
 Clinical stage | |||||
  ≤ 2 | 48 (43.6) | 8 (44.4) | 17 (41.5) | 23 (45.1) | 0.93 |
  > 2 | 62 (56.4) | 10 (55.6) | 24 (58.5) | 28 (54.9) |  |
 NPI | |||||
  Good | 56 (50.9) | 12 (66.7) | 19 (46.3) | 25 (49) | 0.332 |
  Poor | 54 (49.1) | 6 (33.3) | 22 (53.7) | 26 (51) |  |
 Molecular subtype | |||||
  Luminal A | 52 (47.3) | 9 (50) | 16 (39) | 27 (52.9) | 0.45 |
  Luminal B | 14 (12.7) | 3 (16.7) | 3 (7.3) | 8 (15.7) |  |
  HER2+ | 7 (6.4) | 1 (5.6) | 4 (9.8) | 2 (3.9) |  |
  Basal | 37 (33.6) | 5 (27.8) | 18 (43.9) | 14 (27.5) |  |
 IHPI | |||||
  Good | 66 (181.6) | 12 (66.7) | 19 (46.3) | 35 (68.6) | 0.25 |
  Moderate | 37 (33.6) | 5 (27.8) | 18 (43.9) | 14 (27.5) |  |
  Poor | 7 (6.4) | 1 (5.6) | 4 (9.8) | 2 (3.9) |  |
Follow-up | |||||
 ESMO | |||||
  Low risk | 41 (37.3) | 9 (50) | 16 (39) | 16 (31.4) | 0.35 |
  High risk | 69 (62.7) | 9 (50) | 25 (61) | 35 (68.6) |  |
 DFS | |||||
  Prolonged | 52 (47.3) | 7 (38.9) | 13 (31.7) | 32 (62.7) | 0.009 |
  Short | 58 (52.7) | 11 (61.1) | 28 (68.3) | 19 (37.3) |  |
 Recurrence | |||||
  Negative | 55 (50) | 9 (50) | 19 (46.3) | 27 (52.9) | 0.82 |
  Positive | 55 (50) | 9 (50) | 22 (53.7) | 24 (47.1) |  |
 OS | |||||
  Prolonged | 53 (48.2) | 2 (11.1) | 8 (19.5) | 43 (84.3) | < 0.001 |
  Short | 57 (51.8) | 16 (88.9) | 33 (80.5) | 8 (15.7) |  |